Drugs / ARGX 111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02055066 | Jan 2014 → Mar 2017 | cancer | argenx | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2017-07-06 | argenx | Results argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore) argenx.com ↗
Partial response and stable disease were observed, respectively, in one and nine of 24 heavily pretreated patients with MET-positive malignancies, both MET-gene-amplified and with MET overexpression. |
| 2016-06-01 | argenx | Results argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111 argenx.com ↗ |
| 2015-05-28 | argenx | Results arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO argenx.com ↗
The maximum tolerated dose (MTD) was determined at 3 mg/kg every 3 weeks. |
| 2014-09-16 | argenx | Regulatory arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States argenx.com ↗ |
| 2013-09-16 | argenx | Regulatory arGEN-X initiates Phase Ib study of ARGX-111 in cancer argenx.com ↗
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARGX 111 | “This Phase 1b trial will characterize the safety profile of ARGX 111 and will thus provide the first elements towards establishing an accurate risk-benefit assessment for ARGX...” NCT02055066 ↗ |
| Action | Inhibit | “antibody blocking the function of the oncogene c-met” NCT02055066 ↗ |